Katherine Knight, APRN
Primary Care · Little Rock, ARNPI 1659879583
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Novo Nordisk at 30.8% of the total. 2025 is the largest year on record at $301, 4.6 times the $65 reported in 2021.
Across 21 payments — averaging $26.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$170
- Astellas Pharma Global Development$128
- Abbott$63
- AstraZeneca$40
- Otsuka America Pharmaceutical, Inc.$32
- ARS Pharmaceuticals Operations, Inc.$31
- plus $88 from 5 others
What the payments were for
- Food & beverage$551100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 5 | $170 |
| Astellas Pharma Global Development | 1 | $128 |
| Abbott | 3 | $63 |
| AstraZeneca | 3 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $31 |
| AbbVie | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $14 |
| GSK | 1 | $14 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vyloy$128
How this compares
$551 in reported general payments places this provider in the 65th percentile of 76 primary care providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 115 | $114,184 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 93 | $64,818 |
| FarxigaDapagliflozin Propanediol | 61 | $61,327 |
| EliquisApixaban | 63 | $45,261 |
| XareltoRivaroxaban | 49 | $36,200 |
| TrulicityDulaglutide | 34 | $32,642 |
| JardianceEmpagliflozin | 35 | $32,002 |
| MyrbetriqMirabegron | 46 | $27,357 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 45 | $24,782 |
| JanuviaSitagliptin Phosphate | 27 | $20,811 |
| RexultiBrexpiprazole | 12 | $18,606 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $12,737 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $11,909 |
| RybelsusSemaglutide | 11 | $9,971 |
| LinzessLinaclotide | 16 | $9,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $170 | $124,155126 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $14 | $108,534189 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere, Symbicort | $40 | $88,845129 claims |
| PfizerEliquis, Lyrica | $14 | $52,37475 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $14 | $38,61048 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $32 | $18,60612 claims |
| AbbVieLinzess | $28 | $9,23716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 76 primary care providers in Arkansas.
Other primary care in Little Rock
- Chelsea PressonLittle Rock$22K
- Katherine ThompsonLittle Rock$10K
- Krystalyn WilliamsLittle Rock$3K
- Vallon WilliamsLittle Rock$2K
- Jamie FergusonLittle Rock$146
- Meagan RipleyLittle Rock$120
- Christy ReedLittle Rock$101
- Andrew OliverMaumelle$45K
- Stephen RohrerWynne$15K
- Chelsea MarquisSpringdale$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.